PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe
LYON, France--( BUSINESS WIRE )--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announced today that it has entered into a definitive agreement with Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the
View HTML
Toggle Summary ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.
ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.   Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins.
View HTML
Toggle Summary ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia
ERYTECH Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia June 17, 2012 05:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--The oral presentation will be held on June 17th 2012 by Prof. Dr.
View HTML
Toggle Summary ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency
ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 08:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )-- ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and
View HTML
Toggle Summary ERYTECH Pharma receives € 7 million from OSEO to lead the TEDAC personalized medicine project in cancer
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
View HTML
Toggle Summary ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer
LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- The first clinical trial using Graspa® on a solid tumor. A good safety profile for Graspa® in last-line therapy patients. A major step forward in its flagship product deployment in solid tumors. ERYTECH Pharma has just completed the enrollment of
View HTML
Toggle Summary ERYTECH Pharma and Genzyme Corporation sign collaborative research agreement in rare diseases
Lyon (France) – October 12th, 2010 ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.
View HTML
Toggle Summary ERYtech Pharma has been awarded ISO 9001:2008 Certification
Lyon (France), Philadelphia (USA), November 24 2009. ERYtech Pharma has been awarded ISO9001:2008 Certification. The International Organization for Standardization is the world’s leading International Standards developer. ISO 9001:2008 specifies the requirements which have been fulfilled by
View HTML
Top